Phenominer Database Results (157 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Clinical Measurement Notes Record ID Study ID
WKY serum total cholesterol level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male 0 days 12 88.0 mg/dl 5.0 17.32 serum total cholesterol measurement test 0.0 PA IV 50mg/kg 0 100407 2479
WKY serum triglyceride level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male 0 days 11 231.0 mg/dl 25.0 82.92 serum triglyceride analysis 0.0 PA IV 50mg/kg 19 days 100410 2479
WKY serum triglyceride level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male 0 days 12 73.0 mg/dl 5.0 17.32 serum triglyceride analysis 0.0 PA IV 50mg/kg 0 100413 2479
WKY afferent arteriolar plasma protein concentration puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male 0 days 6 4.7 g/dl 0.2 0.49 plasma total protein analysis renal afferent arteriole 0.0 PA IV 50mg/kg 23 days rt 100568 2479
WKY efferent arteriolar plasma protein concentration puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male 0 days 9 8.1 g/dl 0.2 0.6 plasma total protein analysis renal efferent arteriole 0.0 PA IV 50mg/kg 0 ce 100575 2479
WKY afferent colloid osmotic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 18.0 mmHg 0.3 0.85 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 pia 100581 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 4.36 ml/min 0.36 0.8 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100602 2479
WKY glomerular capillary ultrafiltration coefficient puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 0.16 nl/(s x mmHg) 0.05 0.1 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg 0 kf 100617 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 67.0 nl/min 13.0 29.07 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 sngfr 100608 2479
WKY afferent arteriolar plasma flow rate puromycin aminonucleoside (50 mg/kg) (for 0.5 hours) then saralasin (0.3 mg/kg/hr) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 314.0 nl/min 34.0 76.03 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 qa 100613 2479
WKY glomerular capillary hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 5 62.0 mmHg 2.0 4.47 micropuncture fluid collection 0.0 PA IV 50mg/kg 0 pgc 100614 2479
WKY glomerular capillary ultrafiltration coefficient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.04 nl/(s x mmHg) 0.0 0.01 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg 0 kf 100590 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male 0 days 5 245.0 g 12.0 26.83 body weighing method 0.0 PA IV 50mg/kg 15 days 100429 2479
WKY body weight puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male 0 days 8 418.0 g 15.0 42.43 body weighing method 0.0 PA IV 50mg/kg 490 days 100434 2479
WKY hematocrit puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male 0 days 8 44.0 % 1.0 2.83 hematocrit analysis 0.0 PA IV 50mg/kg 490 days 100443 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 1.14 ml/min 0.13 0.37 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100461 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 6 0.84 x 10E10 dyne x s/cm5 0.1 0.24 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days re 100558 2479
WKY total arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 6 2.43 x 10E10 dyne x s/cm5 0.28 0.69 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 15 days rt 100563 2479
WKY serum total cholesterol level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male 0 days 11 240.0 mg/dl 15.0 49.75 serum total cholesterol measurement test 0.0 PA IV 50mg/kg 19 days 100404 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 9 3.79 ml/min 0.19 0.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100467 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 9 5.45 ml/min 0.19 0.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100471 2479
WKY urine sodium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male 0 days 9 0.33 mEq/d 0.04 0.13 urine sodium analysis 0.0 PA IV 50mg/kg 0 100503 2479
WKY urine sodium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male 0 days 8 0.73 mEq/d 0.2 0.57 urine sodium analysis 0.0 PA IV 50mg/kg 490 days 100506 2479
WKY glomerular capillary hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 68.0 mmHg 2.0 6.0 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pgc 100535 2479
WKY efferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 24.0 x 10E10 dyne x s/cm5 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 pe 100546 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 7 3.66 ml/min 0.62 1.64 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100464 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.28 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100477 2479
WKY plasma sodium level controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male 0 days 8 148.0 mmol/l 2.0 5.66 automated plasma analysis 0.0 PA IV 50mg/kg 0 100486 2479
WKY total arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 1.53 x 10E10 dyne x s/cm5 0.12 0.34 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 rt 100566 2479
WKY urine sodium excretion rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male 0 days 8 0.3 mEq/d 0.04 0.12 urine sodium analysis 0.0 PA IV 50mg/kg 0 100504 2479
WKY urine potassium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male 0 days 7 0.2 mEq/d 0.03 0.08 urine potassium analysis 0.0 PA IV 50mg/kg 15 days 100509 2479
WKY urine total protein excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male 0 days 12 13.0 mg/d 1.0 3.46 metabolic cage urine volume measurement method 0.0 PA IV 50mg/kg 0 100401 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 82.0 nl/min 10.0 22.36 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 sngfr 100609 2479
WKY efferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 14.0 mmHg 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days pie 100583 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male 0 days 5 119.0 mmHg 3.0 6.71 tail cuff plethysmography 0.0 PA IV 50mg/kg 0 100592 2479
WKY serum albumin level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male 0 days 12 3.6 g/dl 0.1 0.35 radial immunodiffusion assay 0.0 PA IV 50mg/kg 0 100420 2479
WKY single nephron filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.31 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 snff 100525 2479
WKY serum total cholesterol level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male 0 days 12 104.0 mg/dl 10.0 34.64 serum total cholesterol measurement test 0.0 PA IV 50mg/kg 0 100408 2479
WKY serum triglyceride level controlled enalapril content drinking water (50 mg/l) (for 26 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male 0 days 10 240.0 mg/dl 19.0 60.08 serum triglyceride analysis 0.0 PA IV 50mg/kg 19 days 100411 2479
WKY efferent arteriolar plasma protein concentration controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male 0 days 8 7.5 g/dl 0.3 0.85 plasma total protein analysis renal efferent arteriole 0.0 PA IV 50mg/kg 0 ce 100576 2479
WKY efferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 33.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 pie 100585 2479
WKY glomerular capillary ultrafiltration coefficient controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.11 nl/(s x mmHg) 0.03 0.07 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg 0 kf 100591 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 1.22 ml/min 0.03 0.07 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100596 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 4.6 ml/min 0.1 0.22 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100601 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.29 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100606 2479
WKY glomerular capillary ultrafiltration coefficient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 0.06 nl/(s x mmHg) 0.02 0.04 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg 0 kf 100616 2479
WKY plasma renin activity level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male 0 days 12 7.4 ng/ml/h 0.8 2.77 radioimmunoassay 0.0 PA IV 50mg/kg 0 100425 2479
WKY plasma renin activity level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male 0 days 12 206.8 ng/ml/h 20.7 71.71 radioimmunoassay 0.0 PA IV 50mg/kg 0 100426 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male 0 days 8 305.0 g 6.0 16.97 body weighing method 0.0 PA IV 50mg/kg 0 100432 2479
WKY hematocrit controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male 0 days 5 35.0 % 1.0 2.24 hematocrit analysis 0.0 PA IV 50mg/kg 23 days 100438 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male 0 days 7 112.0 mmHg 5.0 13.23 tail cuff plethysmography 0.0 PA IV 50mg/kg 15 days 100446 2479
WKY systolic blood pressure controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male 0 days 5 95.0 mmHg 9.0 20.12 tail cuff plethysmography 0.0 PA IV 50mg/kg 15 days 100447 2479
WKY glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 0.38 ml/min 0.08 0.18 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100456 2479
WKY single nephron filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 6 0.09 null 0.0 0.01 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days snff 100523 2479
WKY afferent arteriolar plasma flow rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 8 244.0 nl/min 21.0 59.4 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 afferent arteriolar plasma flow rate 100531 2479
WKY glomerular transcapillary hydraulic pressure gradient controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 31.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 dp 100551 2479
WKY afferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 1.49 x 10E10 dyne x s/cm5 0.11 0.33 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 ra 100555 2479
WKY plasma renin activity level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male 0 days 11 8.8 ng/ml/h 1.0 3.32 radioimmunoassay 0.0 PA IV 50mg/kg 23 days 100422 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 3.95 ml/min 0.7 1.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100465 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.28 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100480 2479
WKY plasma sodium level controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male 0 days 9 146.0 mmol/l 3.0 9.0 automated plasma analysis 0.0 PA IV 50mg/kg 490 days 100489 2479
WKY urine potassium excretion rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male 0 days 5 0.29 mEq/d 0.09 0.19 urine potassium analysis 0.0 PA IV 50mg/kg 15 days 100510 2479
WKY urine total protein excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male 0 days 11 112.0 mg/d 17.0 56.38 metabolic cage urine volume measurement method 0.0 PA IV 50mg/kg 15 days 100398 2479
WKY efferent arteriolar hydraulic pressure enalapril (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 24.0 mmHg 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pt 109969 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 8 4.15 ml/min 0.32 0.91 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100468 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 1.19 ml/min 0.08 0.18 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100599 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 4.37 ml/min 0.24 0.54 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100603 2479
WKY afferent arteriolar plasma protein concentration controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male 0 days 8 5.5 g/dl 0.1 0.28 plasma total protein analysis renal afferent arteriole 0.0 PA IV 50mg/kg 0 ca 100571 2479
WKY afferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 18.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 ce 100580 2479
WKY efferent colloid osmotic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 29.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 pie 100586 2479
WKY glomerular capillary ultrafiltration coefficient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 6 0.02 nl/(s x mmHg) 0.0 0.01 inulin analysis by liquid phase colorimetry glomerular capillary 0.0 PA IV 50mg/kg 15 days kf 100588 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 1.24 ml/min 0.07 0.16 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100598 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 65.0 nl/min 9.0 20.12 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 sngfr 100610 2479
WKY glomerular capillary hydraulic pressure puromycin aminonucleoside (50 mg/kg) (between 56 and 70 days) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 5 51.0 mmHg 3.0 6.71 micropuncture fluid collection 0.0 PA IV 50mg/kg 0 pgc 100615 2479
WKY body weight puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male 0 days 11 249.0 g 11.0 36.48 body weighing method 0.0 PA IV 50mg/kg 15 days 100392 2479
WKY hematocrit puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male 0 days 7 39.0 % 1.0 2.65 hematocrit analysis 0.0 PA IV 50mg/kg 23 days 100437 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male 0 days 8 113.0 mmHg 4.0 11.31 tail cuff plethysmography 0.0 PA IV 50mg/kg 490 days 100452 2479
WKY glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 1.25 ml/min 0.09 0.25 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100459 2479
WKY afferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 1.04 x 10E10 dyne x s/cm5 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 ra 100556 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 1.54 x 10E10 dyne x s/cm5 0.12 0.36 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 re 100560 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 8 4.18 ml/min 0.47 1.33 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100470 2479
WKY plasma potassium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male 0 days 8 5.0 mmol/l 0.4 1.13 automated plasma analysis 0.0 PA IV 50mg/kg 490 days 100497 2479
WKY urine sodium excretion rate controlled enalapril content drinking water (50 mg/kg) (for 497 days) then puromycin aminonucleoside (50 mg/l) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male 0 days 9 0.69 mEq/d 0.24 0.73 urine sodium analysis 0.0 PA IV 50mg/kg 490 days 100507 2479
WKY urine potassium excretion rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male 0 days 8 0.49 mEq/d 0.04 0.12 urine potassium analysis 0.0 PA IV 50mg/kg 0 100513 2479
WKY urine potassium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male 0 days 8 1.71 mEq/d 0.35 0.98 urine potassium analysis 0.0 PA IV 50mg/kg 490 days 100515 2479
WKY urine total protein excretion rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male 0 days 10 115.0 mg/d 10.0 31.62 metabolic cage urine volume measurement method 0.0 PA IV 50mg/kg 15 days 100399 2479
WKY serum albumin level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male 0 days 12 3.8 g/dl 0.1 0.35 radial immunodiffusion assay 0.0 PA IV 50mg/kg 0 100419 2479
WKY plasma renin activity level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. renin activity male 0 days 10 100.3 ng/ml/h 18.6 58.82 radioimmunoassay 0.0 PA IV 50mg/kg 23 days 100423 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 6 17.0 nl/min 2.0 4.9 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days sngfr 100518 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 50.0 nl/min 3.0 9.0 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 sngfr 100520 2479
WKY urine total protein excretion rate controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. total urine protein amount male 0 days 12 10.0 mg/d 1.0 3.46 metabolic cage urine volume measurement method 0.0 PA IV 50mg/kg 0 100402 2479
WKY afferent arteriolar plasma flow rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 6 186.0 nl/min 17.0 41.64 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days afferent arteriolar plasma flow rate 100528 2479
WKY glomerular capillary hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 50.0 mmHg 3.0 7.35 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days pgc 100533 2479
WKY mean proximal tubular hydraulic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 16.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pt 100541 2479
WKY glomerular transcapillary hydraulic pressure gradient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 48.0 mmHg 2.0 6.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 dp 100550 2479
WKY efferent arteriolar hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 22.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pt 109968 2479
WKY efferent arteriolar hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 21.0 mmHg 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days pt 109966 2479
WKY plasma sodium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male 0 days 7 149.0 mmol/l 3.0 7.94 automated plasma analysis 0.0 PA IV 50mg/kg 23 days 100482 2479
WKY plasma potassium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male 0 days 7 5.9 mmol/l 0.3 0.79 automated plasma analysis 0.0 PA IV 50mg/kg 23 days 100491 2479
WKY plasma potassium level controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male 0 days 8 4.7 mmol/l 0.3 0.85 automated plasma analysis 0.0 PA IV 50mg/kg 0 100495 2479
WKY efferent arteriolar plasma protein concentration puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male 0 days 6 5.0 g/dl 0.1 0.24 plasma total protein analysis renal efferent arteriole 0.0 PA IV 50mg/kg 23 days ce 100573 2479
WKY glomerular transcapillary hydraulic pressure gradient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 35.0 mmHg 3.0 7.35 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days dp 100548 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) (for 70 days) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male 0 days 5 118.0 mmHg 4.0 8.94 tail cuff plethysmography 0.0 PA IV 50mg/kg 70 days 100593 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.28 null 0.03 0.09 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100607 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male 0 days 10 241.0 g 5.0 15.81 body weighing method 0.0 PA IV 50mg/kg 15 days 100393 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male 0 days 9 395.0 g 7.0 21.0 body weighing method 0.0 PA IV 50mg/kg 490 days 100435 2479
WKY hematocrit puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male 0 days 9 43.0 % 1.0 3.0 hematocrit analysis 0.0 PA IV 50mg/kg 0 100440 2479
WKY systolic blood pressure controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male 0 days 8 100.0 mmHg 1.0 2.83 tail cuff plethysmography 0.0 PA IV 50mg/kg 0 100450 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 7 0.31 ml/min 0.05 0.13 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100455 2479
WKY single nephron filtration fraction controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.26 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100526 2479
WKY glomerular capillary hydraulic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 46.0 mmHg 2.0 5.66 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pgc 100536 2479
WKY mean proximal tubular hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 15.0 mmHg 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days pt 100538 2479
WKY mean proximal tubular hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 19.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pt 100540 2479
WKY serum albumin level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male 0 days 10 1.4 g/dl 0.1 0.32 radial immunodiffusion assay 0.0 PA IV 50mg/kg 23 days 100417 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 0.09 null 0.01 0.02 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100474 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.34 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100476 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.27 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100479 2479
WKY plasma sodium level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male 0 days 5 138.0 mmol/l 2.0 4.47 automated plasma analysis 0.0 PA IV 50mg/kg 23 days 100483 2479
WKY plasma sodium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male 0 days 9 148.0 mmol/l 1.0 3.0 automated plasma analysis 0.0 PA IV 50mg/kg 0 100485 2479
WKY urine potassium excretion rate controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male 0 days 9 2.16 mEq/d 0.27 0.82 urine potassium analysis 0.0 PA IV 50mg/kg 490 days 100516 2479
WKY efferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 0.5 x 10E10 dyne x s/cm5 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 re 100561 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 7 0.09 null 0.0 0.01 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100473 2479
WKY body weight puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male 0 days 12 323.0 g 5.0 17.32 body weighing method 0.0 PA IV 50mg/kg 0 100395 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male 0 days 5 127.0 mmHg 5.0 11.18 tail cuff plethysmography 0.0 PA IV 50mg/kg 0 100594 2479
WKY single nephron glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 61.0 nl/min 3.0 8.49 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100521 2479
WKY body weight controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male 0 days 12 312.0 g 4.0 13.86 body weighing method 0.0 PA IV 50mg/kg 0 100396 2479
WKY afferent arteriolar plasma protein concentration puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood total protein amount male 0 days 9 5.6 g/dl 0.1 0.3 plasma total protein analysis renal afferent arteriole 0.0 PA IV 50mg/kg 0 ca 100570 2479
WKY serum triglyceride level controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood triglyceride amount male 0 days 12 72.0 mg/dl 9.0 31.18 serum triglyceride analysis 0.0 PA IV 50mg/kg 0 100414 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 1.49 ml/min 0.09 0.2 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100597 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 3.9 ml/min 0.2 0.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100600 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.32 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100604 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.32 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100605 2479
WKY afferent arteriolar plasma flow rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 270.0 nl/min 44.0 98.39 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 qa 100612 2479
WKY body weight puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male 0 days 7 245.0 g 9.0 23.81 body weighing method 0.0 PA IV 50mg/kg 15 days 100428 2479
WKY body weight puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. body mass male 0 days 9 297.0 g 4.0 12.0 body weighing method 0.0 PA IV 50mg/kg 0 100431 2479
WKY hematocrit controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male 0 days 8 43.0 % 1.0 2.83 hematocrit analysis 0.0 PA IV 50mg/kg 0 100441 2479
WKY hematocrit controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. erythrocyte quantity male 0 days 9 42.0 % 1.0 3.0 hematocrit analysis 0.0 PA IV 50mg/kg 490 days 100444 2479
WKY systolic blood pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male 0 days 9 121.0 mmHg 2.0 6.0 tail cuff plethysmography 0.0 PA IV 50mg/kg 0 100449 2479
WKY systolic blood pressure controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. arterial blood pressure trait male 0 days 9 96.0 mmHg 2.0 6.0 tail cuff plethysmography 0.0 PA IV 50mg/kg 490 days 100453 2479
WKY glomerular filtration rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 1.28 ml/min 0.06 0.18 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100458 2479
WKY glomerular filtration rate controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 1.43 ml/min 0.09 0.27 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100462 2479
WKY serum albumin level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood albumin amount male 0 days 11 1.3 g/dl 0.1 0.33 radial immunodiffusion assay 0.0 PA IV 50mg/kg 23 days 100416 2479
WKY total arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 3.03 x 10E10 dyne x s/cm5 0.22 0.66 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 rt 100565 2479
WKY serum total cholesterol level controlled enalapril content drinking water (50 mg/l) (for 26 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood cholesterol amount male 0 days 10 360.0 mg/dl 45.0 142.3 serum total cholesterol measurement test 0.0 PA IV 50mg/kg 19 days 100405 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 22.0 x 10E10 dyne x s/cm5 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 pe 100545 2479
WKY afferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 6 1.6 x 10E10 dyne x s/cm5 0.22 0.54 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 15 days ra 100553 2479
WKY plasma sodium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood sodium amount male 0 days 8 142.0 mmol/l 5.0 14.14 automated plasma analysis 0.0 PA IV 50mg/kg 490 days 100488 2479
WKY plasma potassium level controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male 0 days 5 5.8 mmol/l 0.4 0.89 automated plasma analysis 0.0 PA IV 50mg/kg 23 days 100492 2479
WKY plasma potassium level puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male 0 days 9 4.4 mmol/l 0.1 0.3 automated plasma analysis 0.0 PA IV 50mg/kg 0 100494 2479
WKY plasma potassium level controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood potassium amount male 0 days 9 4.7 mmol/l 0.3 0.9 automated plasma analysis 0.0 PA IV 50mg/kg 490 days 100498 2479
WKY urine sodium excretion rate controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male 0 days 5 0.04 mEq/d 0.01 0.03 urine sodium analysis 0.0 PA IV 50mg/kg 15 days 100501 2479
WKY urine potassium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine potassium amount male 0 days 9 0.5 mEq/d 0.04 0.13 urine potassium analysis 0.0 PA IV 50mg/kg 0 100512 2479
WKY urine sodium excretion rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. urine sodium amount male 0 days 7 0.03 mEq/d 0.01 0.02 urine sodium analysis 0.0 PA IV 50mg/kg 15 days 100500 2479
WKY afferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 12.0 mmHg 0.3 0.73 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 15 days pia 100578 2479
WKY single nephron glomerular filtration rate puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 57.0 nl/min 8.0 17.89 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 sngfr 100611 2479
WKY afferent arteriolar plasma flow rate puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 9 169.0 nl/min 14.0 42.0 inulin analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 afferent arteriolar plasma flow rate 100530 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 6 21.0 x 10E10 dyne x s/cm5 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days pe 100543 2479